TG Therapeutics, Inc. (NASDAQ:TGTX – Get Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.83 and traded as high as $6.86. TG Therapeutics shares last traded at $6.59, with a volume of 1,447,417 shares traded.
Wall Street Analysts Forecast Growth
TGTX has been the subject of several recent analyst reports. StockNews.com raised shares of TG Therapeutics to a “sell” rating in a research note on Friday, June 17th. B. Riley lowered their target price on shares of TG Therapeutics from $23.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 13th. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $21.25.
TG Therapeutics Trading Down 3.2 %
The company has a debt-to-equity ratio of 0.53, a current ratio of 4.68 and a quick ratio of 4.68. The stock has a market cap of $884.72 million, a price-to-earnings ratio of -2.82 and a beta of 2.19. The company’s fifty day moving average price is $6.83 and its 200-day moving average price is $6.83.
Institutional Investors Weigh In On TG Therapeutics
TG Therapeutics Company Profile
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
- Get a free copy of the StockNews.com research report on TG Therapeutics (TGTX)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.